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TRANSPLANTATION
Rapid quantification of naive alloreactive T cells by TNF- production
and correlation with allograft rejection in mice
Michael A. Brehm,1 Julie Mangada,2 Thomas G. Markees,2 Todd Pearson,2 Keith A. Daniels,1
Thomas B. Thornley,2 Raymond M. Welsh,1 Aldo A. Rossini,2 and Dale L. Greiner2
1Department of Pathology and 2Department of Medicine, University of Massachusetts Medical School, Worcester, MA
Allograft transplantation requires chronic
immunosuppression, but there is no effec-
tive strategy to evaluate the long-term
maintenance of immunosuppression
other than assessment of graft function.
The ability to monitor naive alloreactive
T cells would provide an alternative guide
for drug therapy at early, preclinical stages
of graft rejection and for evaluating toler-
ance-inducing protocols. To detect and
quantify naive alloreactive T cells directly
ex vivo, we used the unique ability of
naive T cells to rapidly produce TNF- but
not IFN-. Naive alloreactive T cells were
identified by the production of TNF-
after a 5-hour in vitro stimulation with
alloantigen and were distinguished from
effector/memory alloreactive T cells by
the inability to produce IFN-. Moreover,
naive alloreactive T cells were not de-
tected in mice tolerized against specific
alloantigens. The frequency of TNF-–
producing cells was predictive for rejec-
tion in an in vivo cytotoxicity assay and
correlated with skin allograft rejection.
Naive alloreactive T cells were also de-
tected in humans, suggesting clinical rel-
evance. We conclude that rapid produc-
tion of TNF- can be used to quantify
naive alloreactive T cells, that it is abro-
gated after the induction of tolerance, and
that it is a potential tool to predict allo-
graft rejection. (Blood. 2007;109:819-826)
© 2007 by The American Society of Hematology
Introduction
The ability to reject allografts is a hallmark of the immune system
and is mediated by the vigorous immune response generated
against MHC-disparate haplotypes. To prevent allograft rejection
in patients undergoing transplantation, chronic immunosuppressive
drug therapy is required.1-3 Clinical parameters of graft function
currently guide drug choice and dosage during immunosuppressive
therapy, but significant organ damage can occur prior to recogni-
tion of ongoing but subclinical graft rejection. The ability to
identify and quantify alloreactive T cells prior to the appearance of
clinical signs of graft rejection could improve patient management
or the use of immunosuppressive drugs for maintaining allograft
survival. A protocol to rapidly quantify naive and effector/memory
alloreactive T cells could also be used to evaluate tolerance
induction protocols as they enter clinical transplantation trials.4-6
T cells are an important component of allograft rejection, and
alloreactive T cells represent a substantial proportion of the naive
T-cell repertoire. Between 0.1% and 10% of naive T cells within an
individual are estimated to be reactive with any unique allogeneic
MHC haplotype.7-10 Assays that have been used to quantify
alloreactive T cells, including limiting dilution analysis,11,12 enzyme-
linked immunospot assays,13-16 and in vivo proliferation assays,10,13,15,17
require an extended in vitro culture period. However, these assays have
not been translated effectively into the clinic and do not permit direct
and rapid identification of naive alloreactive T cells.
Naive T cells are thought to acquire full functionality only after
a programmed pathway of differentiation that is initiated by antigen
recognition.18-22 The lack of measurable functions and the ex-
tremely low frequencies of naive T cells specific for any individual
antigen have precluded the quantification of naive T cells by
protocols that are commonly used to enumerate effector and
memory T cells.23-25 We have recently observed that naive CD8
T cells rapidly produce TNF- but not IFN- following TCR
engagement,26 and that this differential cytokine profile serves as a
marker for naive T cells. The relatively high frequency of
alloreactive T cells in a naive host makes this approach a potential
methodology for identification and quantification of naive alloreac-
tive T cells.
We demonstrate here that naive alloreactive T cells in mice and
in humans are readily detectable by the rapid production of TNF-
after a short-term in vitro stimulation with alloantigen. The
differential expression of TNF- and IFN- can distinguish
between naive and effector/memory alloreactive T cells, and
moreover, the frequency of alloreactive CD8 T cells estimated by
TNF- production correlates with allograft survival.
Materials and methods
Mice
Male C57BL/6J (C57BL/6, H2b), BALB/cJ (H2d), and CBA/J (H2k) were
purchased from the National Cancer Institute (Bethesda, MD) or from the
Jackson Laboratory (Bar Harbor, ME) and used at 6 to 10 weeks of age.
KB5.CBA TCR transgenic mice were obtained from Dr John Iacomini
(Harvard Medical School, Boston, MA). The TCR transgene is expressed in
CBA (H2k) mice by CD8 T cells, and the transgenic TCR recognizes
H2-Kb.27 B10.BR D10 TCR transgenic mice were obtained from the late Dr
Charles Janeway (Yale University, New Haven, CT). The D10 TCR
transgene was backcrossed 10 generations onto the CBA/J background and
is maintained as a CBA.D10 stock. The D10 TCR transgene is expressed on
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the H2k background and directly recognizes the I-Ab MHC class II
molecule.28 All animals were maintained in accordance with the guidelines
of the Institutional Animal Care and Use Committee of the University of
Massachusetts Medical School.
Isolation of human PBMCs
Human peripheral blood mononuclear cells (PBMCs) were obtained from
healthy volunteers, under signed informed consent in accordance with the
Declaration of Helsinki and approval from the Institutional Review Board
of the University of Massachusetts Medical School. PBMCs were collected
in heparin and purified by Ficoll-Hypaque density centrifugation.
Preparation of LPS-treated splenocytes
Splenocytes were prepared from the indicated mouse strains (2 106 cells/mL in
supplemented RPMI) and were treated with LPS (15g/mL) for 3 days in vitro.
Following incubation, the cultures were washed 3 times with supplemented
RPMI, -irradiated (20 Gy), and frozen at70°C until used.
Intracellular cytokine staining
Cytokine-producing mouse T cells were detected using the Cytofix/
Cytoperm Kit Plus (with GolgiPlug, BD Biosciences, Mountain View, CA),
as described previously.29 Splenocytes (2  106 cells) or peripheral blood
leukocytes (PBLs) from mice were incubated with 250 ng/mL anti–mouse
CD3 monoclonal antibody (mAb; 145-2C11, BD Biosciences) or with the
indicated LPS-treated splenocytes populations (1  106 stimulator cells/
sample) in the presence of 1 U/mL human recombinant IL-2 (BD
Biosciences) and 1 L/mL GolgiPlug at 37°C in the presence of 5% CO2
for 5 hours. Following the incubation, splenocytes were stained with mAb
specific for CD8 (53-6.7), CD4 (RM4-5), and CD11a (M17/4). Samples
were fixed and permeabilized with Cytofix/Cytoperm solution and stained
with mAb specific for IFN- or TNF- (XMG1.2 and MP6-XT22,
respectively; BD Biosciences), or with an IgG1-isotype control (R3-34, BD
Biosciences).
Human PBMCs were incubated in the presence of anti–human CD28,
5 g/mL (CD28.2, BD Biosciences), for a total of 6 hours in AIM-V medium
supplemented with 14% human AB serum (Nabi, Rockville, MD), 16%
MLA-144 supernatant, 10 U/mL rIL-2 (BD Biosciences), 1% L-glutamine, 0.5%
-mercaptoethanol, and 1% HEPES. Anti–human CD3 antibody (HIT3a, BD
Biosciences) was added to some cultures at 100 ng/mL to provide a polyclonal
T-cell stimulation. To stimulate alloreactive T cells, PBMCs were incubated with
CFSE-labeled (0.4 M, Sigma, St Louis, MO) PBMCs derived from an
allogeneic donor or with autologous CFSE-labeled PBMCs at a 1:1 ratio. After 2
hours GolgiPlug (1L/mL) was added to the cultures. After an addition 4 hours,
samples were stained with mAb specific for CD8 (RPA-T8), CD4 (SK3), CD11a
(HI111), and CD3 (UCHT1). Following treatment with Cytofix/Cytoperm
solution, human PBMC samples were stained with mAb specific for IFN- and
TNF- (4S.B3 and MAb11, respectively; BD Biosciences). The samples were
analyzed using a LSR-II (BD Biosciences). To evaluate cytokine production
following allogeneic stimulation, samples were gated on the CFSE low T-cell
populations. Samples were considered positive for TNF production if the values
were more than 3 standard deviations over the mean of TNF produced by T cells
from 12 donors after stimulation with autologous CFSE-labeled PBMCs (0.09%
for CD8 and 0.08% for CD4). The presence of brefeldin A during the majority of
the stimulation period would be expected to minimize the presentation of
alloantigens by the indirect pathway, leading to this assay detecting predomi-
nantly T cells activated by the direct antigen presentation pathway.
Tolerance induction and skin transplantation
Recipient mice were treated with a donor-specific transfusion (DST) and
anti-CD154 mAb, as described previously.30,31 Briefly, a DST consisting of
1  107 spleen cells was injected intravenously on day 7 relative to
transplantation or intracellular cytokine analysis. Cohorts of mice also
received intraperitoneal administration of 0.5 mg purified hamster anti–
mouse anti-CD154 mAb (clone MR1, National Cell Culture Center,
Minneapolis, MN) on days7 and4, 0, and3, whereas other mice were
untreated or received DST only. Mice received a skin allograft on day 0 as
described.30 Thereafter, skin grafts were assessed 3 times weekly.30
Generation of KB5 TCR transgenic synchimeric CBA/J mice
KB5 TCR-transgenic hematopoietic synchimeric chimeras were generated
as described previously.32 The CD8 T cells that develop from KB5 bone
marrow express a transgenic TCR that can be identified using the clonotypic
mAb DES.33 These mice are termed KB5 “synchimeras.”
In vivo cytotoxicity assay
The in vivo cytotoxicity assay was performed as previously described.34,35
Briefly, spleens were harvested from the indicated mouse strains and
single-cell suspensions were prepared. Splenocytes were incubated with
either 2 M or 0.4 M CFSE (Sigma) for 15 minutes at 37°C. Splenocytes
were washed and the populations were combined at equal ratios. Cells
(2  107) were adoptively transferred intravenously into naive recipient
mice or into the indicated recipient mice. Spleens from recipient mice were
harvested 20 hours later, and the survival of each transferred population was
assessed by flow cytometry. To quantify alloreactive CD8T-cell cytotoxic-
ity in the absence of natural killer (NK) cell killing, NK cells were depleted
1 day prior to adoptive transfer of CFSE-labeled cells using anti-NK1.1
antibody (PK136).36 Specific lysis was calculated using the following
equation37: 100  ([(% target population in experimental/% syngeneic
population in experimental) 	 (% target population in NK1.1-depleted
naive/% syngeneic population in NK1.1-depleted naive)]  100). To
determine specific lysis, the survival of allogeneic splenocytes in NK1.1-
depleted naive mice was used as a baseline because optimal survival of
these populations was found under these conditions.
Statistics
Statistical analyses were performed with InStat3 software (GraphPad
Software, San Diego, CA). Three means were compared by one-way
ANOVA and the Tukey-Kramer multiple comparison test, and means of
2 groups were compared by 2-tailed t tests. P values of less than .05 were
considered to be statistically significant.
Results
Naive T cells produce TNF- rapidly after TCR engagement
by anti-CD3
To examine the ability of naive T cells to produce cytokines rapidly
following TCR engagement, splenocytes from C57BL/6 mice were
stimulated with anti-CD3 mAb or left unstimulated for 5 hours, and
CD8 and CD4 T cells were examined for intracellular TNF-
and IFN- expression. No TNF- production was detected in
unstimulated cultures (Figure 1A-B). In contrast, a large proportion
of both CD8 (Figure 1A) and CD4 (Figure 1B) T cells from
naive C57BL/6 mice produced TNF- following anti-CD3 mAb
stimulation (37% 
 1.8% and 33% 
 3.5%, n  6, respectively)
but not IFN-. T cells producing TNF- had a naive phenotype
because the majority of TNF- cells were CD11alo and CD44lo
(Figure 1A-B). These results demonstrate that naive CD4 and
CD8 T cells rapidly produce TNF- following TCR engagement,
extending an observation that we have recently described only for
CD8 T cells.26
Identification of naive alloreactive CD8 and CD4 T cells
by TNF- production
The ability of naive T cells to produce TNF- soon after anti-CD3
mAb stimulation suggests that production of this cytokine may be
used as a marker to detect naive alloreactive T cells that will permit
their identification directly ex vivo. To test this hypothesis, we first
documented that defined alloreactive TCR transgenic T-cell popula-
tions would rapidly produce TNF- on exposure to alloantigen.
KB5 TCR transgenic CD8 T cells that express a TCR that
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recognizes H2-Kb and D10 TCR transgenic CD4 T cells that
express a TCR that directly recognizes I-Ab were examined for
their ability to produce TNF- following stimulation with alloge-
neic targets.
Splenocytes from KB5 TCR transgenic (Figure 1C) and D10
TCR transgenic (Figure 1D) mice were stimulated for 5 hours with
syngeneic (CBA, H2k) or allogeneic (C57BL/6, H2b) splenocytes,
and TNF- and IFN- production was assessed by intracellular
staining. TCR transgenic T cells were identified using clonotypic
antibodies (DES for KB5 CD8 T cells and 3D3 for D10 CD4
T cells). A large proportion of KB5 CD8 T cells (31% 
 3.2%,
n  5; Figure 1C) and D10 CD4 T cells (39% 
 2.4%, n  5;
Figure 1D) produced TNF- but not IFN- following stimulation
with allogeneic splenocytes (C57BL/6). In contrast, only very low
levels of cytokines were produced by KB5 or D10 T cells following
stimulation with syngeneic splenocytes (CBA). The majority of
TNF-–producing KB5 CD8 T cells (40% 
 1.5% of CD44lo
cells) and D10 CD4 (42% 
 4.1% of CD44lo cells) T cells were
naive, as determined by CD44 expression. These results demon-
strate that naive alloreactive TCR transgenic T cells rapidly
produce TNF- following stimulation with the physiologically
relevant level of alloantigen expressed by allogeneic splenocytes.
To determine if naive alloreactive CD8 T cells in a wild-type
(ie, nontransgenic) host could be identified by their rapid produc-
tion of TNF- following allo-stimulation, splenocytes from naive
C57BL/6 mice were incubated in vitro with syngeneic (C57BL/6)
or allogeneic (BALB/c, H2d or CBA, H2k) splenocytes. C57BL/6
T cells that were stimulated with either BALB/c or CBA spleno-
cytes produced TNF- (Figure 2A) but not IFN- (Figure 2B). The
TNF-–producing CD8 T cells were CD11alo and CD44lo (data
not shown), consistent with a naive phenotype. Stimulation with
syngeneic splenocytes (C57BL/6) demonstrated that only very low
background levels of TNF- and IFN- are produced by unstimu-
lated CD8 T cells. Staining levels with isotype controls for
cytokine mAb were always less than 0.1% on T cells stimulated
with allogeneic splenocytes. The total number of naive alloreactive
CD8 T cells in a naive C57BL/6 mouse was estimated using the
percentage of TNF-–producing cells (Figure 2C), and the approxi-
mated frequency is consistent with previous estimations.1-5 To-
gether these results demonstrate that for the first time naive
alloreactive T cells can be identified directly ex vivo by their
production of TNF- in a short-term assay.
Differential production of TNF- and IFN- distinguishes naive
alloreactive CD8 T cells from effector/memory T cells
Antigen-specific effector and memory CD8T cells can be identified by
their numerous effector functions, including production of TNF- and
IFN-, and by the expression of high levels of the activation markers
CD44 and CD11a. The production of TNF- but not IFN- by
antigen-specific naive CD8 T cells should permit them to be distin-
guished from T cells that have had previous exposure to alloantigen.
Naive and effector/memory alloreactive CD8 T cells were
compared directly by evaluating CD8 T cell responses in naive
C57BL/6 mice or “primed” C57BL/6 mice that were inoculated
with a BALB/c (H2d) DST 7 days earlier (Figure 3). Stimulation of
splenocytes from naive C57BL/6 mice by BALB/c (Figure 3A) or
CBA (H2k; Figure 3B) splenocytes led to rapid TNF- production
in CD11alo CD8 T cells, as observed (Figure 2). In contrast, the
CD8 T cells from C57BL/6 mice primed with BALB/c DST that
produced TNF- following an in vitro stimulation with BALB/c
Figure 1. Naive T cells rapidly produce TNF- but not IFN- after TCR engagement. (A-B) Splenocytes from naive C57BL/6 mice were stimulated for 5 hours with
anti-CD3mAb and stained for cell surface markers and for intracellular TNF- and IFN-, as described in “Materials and methods.” Samples were gated on CD8 (A) or CD4
(B) T cells and examined for expression of TNF- or IFN- and for expression of CD11a and CD44. The values represent the percentage of T cells producing cytokine or the
percentage of T cells that were either low or high for CD11a or CD44 that produced TNF-. The data are representative of 5 experiments. (C-D) Splenocytes from (C) naive KB5
TCR CD8 alloreactive transgenic mice or (D) naive D10 TCR CD4 alloreactive transgenic mice were stimulated for 5 hours with either syngeneic (CBA, H2k) or allogeneic
(C57BL/6, H2b) splenocytes and stained as described. For analysis, samples were gated on (C) DESCD8 cells or (D) 3D3CD4 cells. The values represent the percentage
of TCR transgenic T cells positive for TNF- or IFN-. The data are representative of 3 experiments.
Figure 2. Rapid production of TNF- by naive alloreactive CD8 T cells in
C57BL/6 mice. Splenocytes from naive C57BL/6 mice were stimulated with synge-
neic (C57BL/6, H2b) or allogeneic (BALB/c, H2d or CBA, H2k) splenocytes, as
described in “Materials and methods.” Splenocytes were then stained for cell surface
markers and for intracellular (A) TNF- or (B) IFN-. For analysis, samples were
gated on CD8 cells, and the values shown represent the percentage of CD8 T cells
staining positive for either cytokine. The total number of splenic alloreactive CD8
T cells producing TNF- in response to the indicated allo-stimulation is shown in
panel C. The data are representative of 5 experiments. Error bars indicate SD.
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splenocytes had an activated phenotype, being predominantly
CD11ahi (Figure 3A). As expected, the H2k-specific CD8 T cells
from BALB/c-primed C57BL/6 mice maintained a naive pheno-
type (CD11alo), demonstrating the alloantigen specificity of the
“priming” (Figure 3B). In addition, naive H2d-specific CD8
T cells producing TNF- did not synthesize IFN- to the H2d
stimulation, whereas the majority of the H2d-specific CD8 T cells
from C57BL/6 mice primed with BALB/c DST did make IFN-
(Figure 3C). These observations document that naive CD8 T cells
can be distinguished from effector CD8 T cells by their rapid
antigen-specific differential production of TNF- and IFN-.
TNF- and IFN- production can be used to monitor the
efficacy of tolerance induction
The use of costimulation blockade allows for the prolonged survival of
allogeneic grafts in the absence of chronic immunosuppression.31 Our
laboratory’s costimulatory blockade regimen consists of a single DST of
splenocytes and a brief course of anti-CD154 mAb that induces
nonresponsiveness in the T-cell compartment through both deletional
and nondeletional mechanisms.30,31 Our observation that the rapid
production of TNF- permits identification of naive and effector
alloreactive T cells may provide an approach for monitoring the efficacy
of a tolerance induction regimen.
To test this, we quantified the ability of alloreactive CD8 T cells to
produce TNF- and IFN- after costimulatory blockade. C57BL/6 mice
were treated with a BALB/c DST and anti-CD154 mAb according to
our standard protocol.32 The CD8 T cells from mice treated with
costimulation blockade produced only very low levels of TNF- (Figure
3A,D;  0.15% CD8 T cells) or IFN- ( 0.05% CD8 T cells)
following stimulation with BALB/c splenocytes. TNF- production by
T cells in mice treated with costimulation blockade was significantly
less than that observed by T cells from naive C57BL/6 mice (P .05;
Figure 3D). Naive CD8 T cells readily produced TNF- following
stimulation with H2k alloantigens in C57BL/6 mice treated with a
BALB/c DST and anti-CD154 mAb, again demonstrating the alloanti-
gen specificity of the priming DST (Figure 3B). Similar results were
obtained in reciprocal experiments in which C57BL/6 mice were
primed with a CBA (H2k) DST or were tolerized to CBA alloantigens
using our costimulation blockade protocol (Figure S1, available on the
Blood website: see the Supplemental Figure link at the top of the online
article). Together these results demonstrate that TNF- and IFN-
production can be used to distinguish between naive and effector
alloreactive CD8 T cells and that costimulation blockade induces
an alloantigen-specific loss of TNF-– and IFN-–producing
CD8 T cells.
Costimulation blockade leads to both deletion of alloreactive
CD8 T cells and to loss of function
In the majority of C57BL/6 mice that were treated with costimulation
blockade, TNF-–producing, alloreactive CD8 T cells specific to
donor-specific alloantigen were greatly reduced in frequency. To deter-
mine if alloreactive CD8 T cells were deleted or if the cells had lost
their ability to produce TNF-, we used KB5 synchimeric mice that
circulate a trace population of alloreactive TCR transgenic CD8T cells
that can be quantified using the DES clonotypic mAb. The frequency of
DESCD8 T cells was measured in naive KB5-synchimeras and in
synchimeric mice that were given C57BL/6 DST and anti-CD154 mAb
costimulation blockade.
The percentage (Figure 4A) and total number (Figure 4B) of
Figure 4. Costimulation blockade leads to the deletion of alloreactive CD8
T cells and a loss in TNF- production after allo-stimulation. Splenocytes from either
naive KB5 bone marrow synchimeric mice or synchimeric mice treated with costimulation
blockade were stained for cell surface makers, and the DESCD8 KB5 T cells are shown
as a (A) percentage or (B) as total spleen cell number (n 5). Splenocytes from the
indicated group were stimulated for 5 hours with C57BL/6 (H2b) splenocytes and then
stained for cell surface markers and for TNF-. For analysis, samples were gated on CD8
cells, and the values shown represent the percentage of CD8DES cells producing
TNF- (C-D, n 5). Means were compared with a t test (*P .001). The data are
representative of 2 experiments. Error bars indicate SD.
Figure 3. Naive, effector, and nonresponsive H2d-specific CD8
T cells distinguished by differential expression of cytokines and
activation markers. Splenocytes from naive C57BL/6 mice, from
C57BL/6 mice that were injected with BALB/c splenocytes (BALB/c
DST) 7 days previously, or from C57BL/6 mice that were tolerized with
anti-CD154 and BALB/c DST were stimulated in vitro with either
BALB/c (H2d) splenocytes (A) or CBA (H2k) splenocytes (B), as
described in “Materials and methods.” Samples were then stained for
cell surface markers and for intracellular cytokines. Samples were
gated on CD8 cells, and the values shown represent the percentage
of CD8 T cells staining positive for TNF-. (C) H2d-specific CD8
T cells producing TNF- were evaluated for IFN- production and the
values represent the percentage of TNF-–producing CD8 T cells
that were positive for IFN-. The total number of CD8 T cells
producing TNF- following stimulation with BALB/c (H2d) splenocytes
is shown in panel D (n  4). One-way ANOVA was used to compare
naive C57BL/6 mice with mice treated with DST or with mice treated
with DST and MR1 (*P  .05). The data are representative of
3 experiments. Error bars indicate SD.
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splenic DESCD8 KB5 T cells were significantly reduced in
synchimeric mice given DST and anti-CD154 mAb as compared to
levels observed in untreated synchimeric mice (P  .001). The few
DESCD8 T cells that remained in mice treated with costimulation
blockade were significantly impaired in their ability to produce TNF-
as compared to DESCD8T cells in naive synchimeras (Figure 4C,D).
The majority of DESCD8 T cells in mice given costimulation
blockade expressed an activated phenotype (57%
 8.9% CD44hi),
whereas few DESCD8 T cells (0.8%
 0.2% CD44hi) in naive
synchimeric mice expressed an activated phenotype.38 These data
indicate that costimulation blockade activates alloreactive T cells,
leading to the deletion of a majority of alloreactive T cells, and that it
impairs the ability of the remaining alloreactive population to produce
TNF- after allogeneic stimulation.
TNF- production correlates with the rejection of skin
allografts in mice treated with costimulation blockade
Treatment with costimulatory blockade prolongs the survival of
allogeneic skin grafts, but these allografts are eventually rejected.
We tested the hypothesis that the frequency of TNF-–producing
cells and their activation phenotype would correlate with skin
allograft rejection in mice treated with costimulation blockade.
TNF-–producing cells were quantified in cohorts of mice that had
intact long-term survival of skin allografts or in mice that had
rejected the skin allograft. A group of 12 C57BL/6 mice were
treated with BALB/c DST plus anti-CD154 mAb and given
transplants of a BALB/c skin allograft according to our standard
protocol.32 Skin allograft survival was monitored over the next 101
days, at which point 4 mice had surviving healthy BALB/c skin
grafts, whereas 8 mice had either completely rejected the allograft
or were in the process of rejecting the allograft (Figure 5). The
ability of the alloreactive CD8 T cells in each group to produce
TNF- and IFN- after in vitro stimulation with either syngeneic
(C57BL/6) or allogeneic (BALB/c) splenocytes was determined.
In mice with intact skin allografts, a population of alloreactive
T cells was detectable by TNF- production, but these cells had a
naive (CD11alo) phenotype and did not produce IFN- (Figure 5A).
In contrast, CD8 T cells from mice that had rejected their skin
allografts had acquired an effector/memory phenotype (CD11ahi)
and produced both TNF- and IFN- in response to allo-
stimulation (Figure 5B). The data shown are representative of the
T-cell responses in each group. The data shown in Figures 3 and 4
demonstrate that early after the induction of tolerance there is a loss
of alloreactive T cells in the host. However, the data in Figure 5
demonstrate that naive alloreactive CD8 T cells (CD11alo, TNF-
but not IFN- production) repopulate recipient mice by 101 days
after costimulation blockade and transplantation, but these alloreac-
tive T cells have not been activated to acquire an effector/memory
phenotype (CD11ahi, TNF- and IFN- production). In mice that
have rejected or are in the process of rejecting their skin allografts,
the alloreactive T cells have acquired a functional, activated
effector/memory phenotype.
Prediction of allograft rejection by TNF- production
The ability to detect alloreactive T cells using TNF- production
should allow the assessment of tolerance induction protocols prior
to allograft transplantation and may be used as a predictive tool for
allograft rejection. To test this, we first quantified TNF- produc-
tion by CD8 T cells in C57BL/6 mice that were treated with
BALB/c DST and anti-CD154 mAb 6 days previously. The same
Figure 5. The activation state of alloreactive T cells correlates with skin
allograft outcome in mice treated with costimulation blockade. C57BL/6 mice
were treated with anti-CD154 mAb and a BALB/c DST and engrafted with BALB/c
skin as described in “Materials and methods.” At 101 days after transplantation, (A) 4
of 12 C57BL/6 mice retained intact BALB/c skin grafts and (B) 8 of 12 mice had
completely rejected the allogeneic skin or were in the process of graft rejection.
Splenocytes were harvested from the recipient mice 101 days after skin transplanta-
tion and stimulated in vitro with syngeneic C57BL/6 (H2b) or allogeneic BALB/c (H2d)
splenocytes. Samples were then stained for cell surface markers and for TNF- or
IFN-. Samples were gated on CD8 cells, and the values shown represent the
percentage of CD8 T cells staining positive for TNF- or IFN-. Representative dot
plots are shown.
Figure 6. TNF- production by alloreactive CD8 T cells
correlates with in vivo cytotoxic activity in mice treated with
costimulation blockade. C57BL/6 mice were (A) left naive, (B)
injected with BALB/c DST, or (C-D) treated with anti-CD154 mAb
and a BALB/c DST. Six days later peripheral blood samples were
stimulated in vitro with BALB/c (H2d) splenocytes and then stained
for cell surface markers and for TNF-. The values shown in the
dot plots represent the percentage of CD8 T cells producing
TNF-. One day after the cytokine assay, CFSE-labeled BALB/c
(H2d) and C57BL/6 (H2b) splenocytes were transferred at equal
ratios into the mice, and the survival of each population was
examined 20 hours later. All recipient mice were treated with a
mAb specific for NK1.1 to deplete NK cells. Survival of the BALB/c
splenocytes is shown in representative histograms, and the values
represent the percent specific lysis of BALB/c splenocytes. A
summary of TNF- production and percent specific lysis is shown
in panel D (n  15). The data are representative of 3 separate
experiments.
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mice were then analyzed for their ability to reject BALB/c
splenocytes using an in vivo cytotoxicity assay 1 day after the
cytokine analysis.34
In naive NK cell-depleted C57BL/6 mice, H2d-specific CD8
T cells were readily detectable by TNF- production, and as
expected, BALB/c (H2d) splenocytes were not rejected in the in
vivo cytotoxicity assay (Figure 6A). CD8 T cells with a naive
phenotype have not yet acquired cytotoxic T-lymphocyte (CTL)
activity and cannot reject allogeneic cells in this assay. In contrast,
C57BL/6 mice that were injected 6 days earlier with BALB/c
DST-generated effector H2d-specific CD8 T cells (TNF- and
CD11ahi) and efficiently rejected BALB/c splenocytes (Figure 6B).
In C57BL/6 mice that were treated with BALB/c DST and
anti-CD154 mAb, 2 TNF- production profiles and 3 distinct
cytotoxicity patterns were observed (Figure 6C-D). Representative
data are shown for each group (Figure 6C) and a summary of the
data are shown in Figure 6D.
The majority of mice treated with DST plus anti-CD154 mAb
(group 1; 10 of 15 mice) had no detectable H2d-specific CD8
T cells as measured by TNF- production and were unable to reject
BALB/c splenocytes in the in vivo cytotoxicity assay, suggesting
that these mice had lost donor-specific effector T-cell function.
Group 2 (2 of 15 mice) had no detectable H2d-specific TNF-–
producing CD8 T cells but displayed low levels of in vivo
cytotoxicity, suggesting that deletion or inactivation of donor-
specific alloreactive T cells was incomplete. The third group (3 of
15 mice) generated a population of TNF-–producing H2d-specific
CD8 T cells that were activated (CD11ahi) and these mice
effectively rejected the BALB/c splenocytes in the in vivo cytotox-
icity assay. These data suggest that costimulation blockade in these
3 mice was ineffective and that the alloreactive CD8 T cells were
primed after injection of DST plus anti-CD154 mAb rather than
rendered nonresponsive. Together, these results document that
TNF- production in response to allo-stimulation correlates closely
with the generation of effector CD8 CTL activity as assessed by
an in vivo cytotoxicity assay.
Detection of TNF- production by alloreactive human T cells
We examined the ability of human T cells to rapidly produce
TNF- or IFN- following ex vivo TCR engagement (Figure 7).
PBMCs were isolated from healthy human donors and then
stimulated in vitro with anti–human CD3 mAb for 6 hours. Both
CD8 and CD4 (Figure 7A) T cells produced TNF- or IFN- (or
both) following stimulation with anti-CD3 antibody, and T cells
that produced only TNF- were the dominant population. We next
determined if alloreactive T cells from humans could be detected
by TNF- production. To test this, PBMCs from donors were
mixed with allogeneic PBMCs or with autologous (syngeneic)
PBMCs that had been labeled with CFSE. After a 6-hour incuba-
tion, TNF- production by the CFSE low T-cell populations was
examined by intracellular staining. Samples were gated on cells
that were CD3 and positive for either CD8 or CD4. Figure 7B-C
shows representative results for CD8 or CD4 T cells derived
from 4 donors that were either stimulated with autologous or
allogeneic PBMCs. TNF-–producing CD8 and CD4 T cells
were detectable in a number of donor PBMCs. The percentage of
CD8 and CD4 T cells producing TNF- from all donor
combinations (12 donors in 36 total combinations) is shown in
Figure 7B-C. Alloreactive CD4 T cells were detected in more
donors relative to alloreactive CD8 T cells. Taken together, these
data suggest that the detection of TNF- production will allow the
identification of alloreactive T cells in humans and may be useful in
Figure 7. Human alloreactive T cells rapidly produce TNF- after TCR engage-
ment. PBMCs from human donors were stimulated with (A) a mAb specific for human
CD3 or (B-C) with either allogeneic or autologous CFSE-labeled PBMCs as
described in “Materials and methods.” After 6 hours samples were stained for cell
surface markers and for TNF- and IFN-. For T cells stimulated with anti-CD3 mAb
(A), samples were gated on CD3 cells and then on either CD8 or CD4 cells and
analyzed for their expression of TNF- or IFN-. The values represent the percentage
of T cells that produced TNF- or IFN-. For T cells stimulated with CFSE-labeled
PBMCs, samples were gated on the CFSE low cells that were CD3 cells and either
(B) CD8 or (C) CD4. The values represent the percentage of T cells that produced
TNF-. Samples were considered positive for TNF- production if the values were
more than 3 standard deviations over the mean of TNF- produced by T cells from 12
donors after stimulation with autologous CFSE-labeled PBMCs (*0.09% for CD8 and
0.08% for CD4). This threshold value is indicated by the horizontal line on the graphs.
The data are representative of 3 experiments with a total of 12 donors in 36
combinations.
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screening potential transplant recipients for reactivity against
specific donor tissues.
Discussion
The ability to identify and distinguish naive alloreactive T cells is
important for monitoring immunosuppressive therapy in patients under-
going transplantation and for evaluation of tolerance induction proto-
cols. In this report, we demonstrate that the unique ability of naive
T cells to rapidly produce TNF- but not IFN- after antigen stimulation
allows the identification of naive alloreactive T cells directly ex vivo.
Our results show that the frequency and activation state of alloreactive
T cells can be rapidly determined ex vivo by simultaneously evaluating
cytokine production and the expression of activation markers, and this
information allowed the prediction of in vivo CTL activity against
allogeneic tissues and correlated with allograft outcome in mice treated
with costimulation blockade. Rapid production of TNF- by naive
alloreactive human T cells suggests that this approach may be applicable
in the clinic.
Alloreactive T cells are actively involved in the rejection of
tissue allografts,9 and the development of protocols to quantify
T-cell reactivity against allogeneic grafts has been a primary focus
for transplantation research.39 Most approaches for the detection of
alloreactive T cells have used the production of IFN- to identify
alloreactive T cells. However, only T cells that have been previ-
ously activated by antigenic stimulation rapidly produce IFN-
when re-exposed to the antigen ex vivo.40 Interestingly, IFN- produc-
ing alloreactive T cells are detectable in hosts that have never been
exposed to alloantigen, and the activation of these cells has been
attributed to cross-reactivity to environmental antigens, including
viral and bacterial infections.41-44 Importantly, the presence of
IFN-–producing alloreactive T cells has been shown to correlate
with the rejection of allogeneic tissues,14,16,45,46 but in these studies,
the frequency of naive alloreactive T cells could not be determined.
Our results demonstrate that TNF- production by activated
alloreactive T cells also correlates with the rejection of allogeneic
tissues and has the additional advantage of identifying naive
alloreactive T cells that would be overlooked in studies evaluating
only IFN- production.
Current transplantation procedures require the chronic adminis-
tration of immunosuppressive drugs to prevent the rejection of the
allograft. An alternative to generalized immunosuppression is the
induction of donor-specific tolerance, which will suppress alloreac-
tive responses while allowing other components of the immune
system to function normally.47 Costimulation blockade has been
used successfully to promote the long-term survival of allogeneic
tissues in mice and in nonhuman primates.31,48-55 We demonstrate
here that TNF- production by T cells can be used to measure the
efficiency of tolerance induction at the time of transplantation and
to identify hosts that may be at an increased risk for graft rejection.
The production of TNF- correlated with rejection of allogeneic
tissues as measured by the in vivo cytotoxicity assay in mice
treated with costimulation blockade. However, there were mice in
which TNF- was not detectable but some cytotoxic activity
against allogeneic targets was observed in vivo. It will be important
in future studies to determine if the TNF-, but in vivo cytotoxicity-
positive hosts display impaired survival of allografts. In addition, it
will be important to determine which type of allograft associates
with TNF- production and in vivo cytotoxicity, because treat-
ments that are required for successful prolongation skin allografts
are more robust than those required for prolongation of islet
allografts.56
The ability of naive alloreactive T cells to produce TNF- may
have important consequences for the generation of responses
against alloantigen in vivo. CD8 T cells have been demonstrated
to amplify the innate immune response against cardiac allografts
within the first 24 hours after transplantation, indicating an early
effector function for the alloreactive T cells.57 Whereas IFN- was
implicated in amplifying the innate response to cardiac allografts,
our results suggest that early TNF- production may also contrib-
ute to this process. TNF- production by naive alloreactive T cells
may also play a role during the induction of tolerance with
costimulation blockade, as the allogeneic DST would be expected
to initially stimulate TNF- production in the host alloreactive
T-cell population. Further study of early T-cell functions that are
activated during the initial stimulation with alloantigen will
advance our understanding on the generation of the alloimmune
response and may aid in the development of more efficient
tolerization techniques.
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